B. Riley kept a Neutral rating on Global Medical REIT (GMRE) with a $9 price target following a transfer of coverage. While Global Medical’s strategy is well suited to the current macro environment, given the high percentage of net lease assets in the portfolio and the stock’s valuation discount versus peers, it is best for investors to wait on the sidelines for the time being given the potential for certain negative catalysts, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMRE:
- Seeking Up to 11% Dividend Yield? Analysts Suggest 2 Dividend Stocks to Buy
- Hold Rating on Global Medical REIT Amid Stable Financials and Market Challenges
- Global Medical REIT Inc. Faces Financial Pressure as Interest Rate Swap Expiry Looms
- Global Medical REIT Reports 2024 Earnings and Strategic Moves
- Global Medical REIT’s Earnings Call: Achievements and Challenges